跳至主要内容
临床试验/CTRI/2025/03/083238
CTRI/2025/03/083238尚未招募不适用

Glucose monitoring by Freestyle Libre in patients with Type 2 diabetes mellitus from India A pooled analysis

Abbott Healthcare Pvt.Ltd.10 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2025年3月24日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,200
试验地点
10
主要终点
Estimate the average TIR across 12-15 centres in patients with Diabetes in India with the help of cross sectional data available

研究概览

简要总结

This study aims to evaluate the average Time in Range (TIR) in Type 2 Diabetes Mellitus (T2DM) patients using the FreeStyle Libre system across 12 centres in India. The secondary objectives include assessing the percentage of patients achieving recommended TIR targets and exploring variations in TIR based on factors such as age, gender, BMI, medication type, and comorbidities. Data from approximately 1500 patients will be analyzed, focusing on key metrics like Time in Range (TIR), Time Above Range (TAR), Time Below Range (TBR), and glucose variability. Statistical analysis will include Spearman’s coefficient and linear regression to determine relationships between various patient characteristics and glycaemic control.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Patients aged above 18 years with a diagnosis of T2D using Libre for glucose monitoring will be included in the study.

排除标准

  • Patients below 18 years as well as patients using continuous glucose monitoring instrument other than Libre will be excluded.
  • Patients having difficulty in handling device and are non-compliant will be excluded.

结局指标

主要结局

Estimate the average TIR across 12-15 centres in patients with Diabetes in India with the help of cross sectional data available

时间窗: Baseline, 4 weeks

次要结局

  • •Estimate % of patients with diabetes in India achieving recommended TIR targets (in line with customized targets based on comorbidities/ type of diabetes)(•Estimate average TIR among different patient profiles with T2DM based on 1) comorbidities 2) Age groups 3) Form of pharmacotherapy (Non Insulin, Basal Insulin, MDI) 4) Duration of diabetes)

研究者

发起方
Abbott Healthcare Pvt.Ltd.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Rohit Bhandari

Indegene Private Limited

研究点 (10)

Loading locations...

相似试验

Free style Libre for diabetes 2 management | 临床试验